U.S. Stocks Movement: Oruka Therapeutics Plunges on October 6 Due to Financing Dilution, Selling Pressure, and High-Level Correction

Oruka Therapeutics October 6 Major Drop Analysis

Keywords: financing dilution, selling pressure, correction from highs

1. As of October 6, 2026, after a cumulative increase of 158.73% for the year, the stock price was at a high level and declined 4.54% over the past five trading days, with short-term profit-taking accelerating the correction.

2. On August 21, 2026, the company filed a mixed securities shelf registration statement of up to $1 billion, indicating that future financing might increase share supply and bring potential dilution pressure.

3. On September 21, 2026, the company's General Counsel sold 10 thousand shares; on September 23, 2026, Fairmount reportedly sold approximately 3.55 million shares, adding to the supply pressure on the stock.

4. On September 23, 2026, ORKA-001 announced 28-week data, showing efficacy improvements, but the incidence of upper respiratory tract infections was 8%, and two serious adverse events were reported; full 52-week data is not expected until December 2026, and long-term safety and sustained efficacy have not yet been fully verified.

(Disclaimer: This content is generated by AI technology based on publicly available information. For reference only and does not constitute investment advice.)